Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun 13;2012(6):CD006828.
doi: 10.1002/14651858.CD006828.pub3.

Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome

Satoshi Kuwabara  1 , Angela Dispenzieri, Kimiyoshi Arimura, Sonoko Misawa, Chiaki Nakaseko
Affiliations

Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome

Satoshi Kuwabara et al. Cochrane Database Syst Rev. .

Abstract

Background: POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome is a rare cause of demyelinating and axonal mixed neuropathy with monoclonal plasma cell proliferative disorder and multiorgan involvement. The pathogenesis of POEMS syndrome is not well understood, but overproduction of vascular endothelial growth factor (VEGF), probably secreted by plasmacytomas, is likely to be responsible for most of the characteristic symptoms. POEMS syndrome is a potentially fatal disease, and patients' quality of life deteriorates because of progressive neuropathy, massive pleural effusion or ascites, or thromboembolic events. There is a need for efficacious therapy to improve prognosis. This is the first update of a review first published in 2008.

Objectives: To assess the effects of treatment for POEMS syndrome.

Search methods: We searched the Cochrane Neuromuscular Disease Group Specialized Register (23 February 2012), CENTRAL (2012, Issue 2), MEDLINE (January 1966 to February 2012), EMBASE (January 1980 to February 2012) and CINAHL Plus (January 1937 to February 2012) for all papers on POEMS syndrome

Selection criteria: We sought all randomized and quasi-randomized controlled trials, and non-randomized controlled studies. Since we discovered no such clinical trials, we assessed and summarized all retrospective case series including five or more patients in the 'Discussion' section.

Data collection and analysis: Two review authors independently reviewed and extracted details of all potentially relevant trials with any treatment for POEMS syndrome. We then collated and summarized information on the outcome.

Main results: We found no randomized or non-randomized prospective controlled trials of treatment for POEMS syndrome. We summarized the results of retrospective case series containing five or more patients in the 'Discussion' section.

Authors' conclusions: There are no randomized or quasi-randomized controlled clinical trials of treatment for POEMS syndrome on which to base practice.

PubMed Disclaimer

Conflict of interest statement

Chiaki Nakaseko, Satoshi Kuwabara, Kimiyoshi Arimura, Sonoko Misawa: none known

Angela Dispenzieri: grants paid to her institution for clinical trials (Celgene, Johnson & Johnson) or to discuss future protocols (Onyx, Millenium). She has received financial support for travel to deliver a lecture from Binding Site. She states that none of these interactions affect the content of the present review.

Update of

References

Additional references

Allam 2008
    1. Allam JS, Kennedy CC, Aksamit TR, Dispenzieri A. Pulmonary manifestations in patients with POEMS syndrome: a retrospective review of 137 patients. Chest 2008;133(4):969‐74. - PubMed
Arimura 2007
    1. Arimura K, Hashiguchi T. Crow‐Fukase syndrome: clinical features, pathogenesis and treatment in Japan. In: Yamamura T, Kira J, Tabira T editor(s). Current Topics in Neuroimmunology. Bologna, Italy: Medimond, 2007:241‐5.
Badros 2005
    1. Badros A, Porter N, Zimrin A. Bevacizumab therapy for POEMS syndrome. Blood 2005;106(3):1135. - PubMed
Bardwick 1980
    1. Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M‐protein, and skin changes: the POEMS syndrome. Report of two cases and a review of the literature. Medicine 1980;59(4):311‐22. - PubMed
Cui 2011
    1. Cui RT, Huang XS, Shi Q, Tian CL, Liu JX, Pu CQ. POEMS (polyneuropathy, organomegaly, endocrinopathy, M‐protein and skin changes) syndrome in China. Internal Medicine Journal 2011;41(6):481‐5. - PubMed
D'Souza 2011
    1. D'Souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA, et al. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow‐up of patients with POEMS syndrome. Blood 2011;118(17):4663‐5. - PubMed
Dispenzieri 2003
    1. Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR, et al. POEMS syndrome: definitions and long‐term outcome. Blood 2003;101(7):2496‐506. - PubMed
Dispenzieri 2004
    1. Dispenzieri A, Moreno‐Aspitia A, Suarez GA, Lacy MQ, Colon‐Otero G, Tefferi A, et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 2004;104(10):3400‐7. - PubMed
Dispenzieri 2005a
    1. Dispenzieri A. POEMS syndrome. Hematology American Society Hematology Education Program 2005;1:360‐7. - PubMed
Dispenzieri 2005b
    1. Dispenzieri A, Gertz MA. Treatment options for POEMS syndrome. Expert Opinion Pharmacotherapy 2005;6(6):945‐53. - PubMed
Dispenzieri 2007a
    1. Dispenzieri A. POEMS syndrome. Blood Reviews 2007;21(6):285‐99. - PubMed
Dispenzieri 2007b
    1. Dispenzieri A, Klein CJ, Mauermann ML. Lenalidomide therapy in a patient with POEMS syndrome. Blood 2007;110(3):1075‐6. - PubMed
Dispenzieri 2008
    1. Dispenzieri A, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, et al. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. European Journal of Haematology 2008;80(5):397‐406. - PMC - PubMed
Dispenzieri 2011
    1. Dispenzieri A. POEMS syndrome: 2011 update on diagnosis, risk‐stratification, and management. American Journal of Hematology 2011;86(7):591‐601. - PubMed
Giglia 2007
    1. Giglia F, Chiapparini L, Fariselli L, Barbui T, Ciano C, Scarlato M, et al. POEMS syndrome: relapse after successful autologous peripheral blood stem cell transplantation. Neuromuscular Disorders 2007;17(11‐12):980‐2. - PubMed
Graham 2006
    1. Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. Journal of Neurology, Neurosurgery, and Psychiatry 2006;77(8):973‐6. - PMC - PubMed
Hashiguchi 2000
    1. Hashiguchi T, Arimura K, Matsumuro K, Otsuka R, Watanabe O, Jonosono M, et al. Highly concentrated vascular endothelial growth factor in platelets in Crow‐Fukase syndrome. Muscle & Nerve 2000;23(7):1051‐6. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Imai 2009
    1. Imai N, Taguchi J, Yagi N, Konishi T, Serizawa M, Kobari M. Relapse of polyneuropathy, organomegaly, endocrinopathy, M‐protein, and skin changes (POEMS) syndrome without increased level of vascular endothelial growth factor following successful autologous peripheral blood stem cell transplantation. Neuromuscular Disorders 2009;19(5):363‐5. - PubMed
Isose 2011
    1. Isose S, Misawa S, Kanai K, Shibuya K, Sekiguchi Y, Nasu S, et al. POEMS syndrome with Guillan‐Barre syndrome‐like acute onset: a case report and review of neurological progression in 30 cases. Journal of Neurology, Neurosurgery, and Psychiatry 2011;82(6):678‐80. - PubMed
Jaccard 2002
    1. Jaccard A, Royer B, Bordessoule D, Brouet JC, Fermand JP. High‐dose therapy and autologous blood stem cell transplantation in POEMS syndrome. Blood 2002;99(8):3057‐9. - PubMed
Jimenez‐Zepeda 2011
    1. Jimenez‐Zepeda VH, Trudel S, Reece DE, Chen C, Rabea AM, Kukreti V. Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantation. American Journal of Hematology 2011;86(10):873‐5. - PubMed
Kanai 2007
    1. Kanai K, Kuwabara S, Misawa S, Hattori T. Failure of treatment with anti‐VEGF monoclonal antibody for long‐standing POEMS syndrome. Internal Medicine 2007;46(6):311‐3. - PubMed
Kaygusuz 2010
    1. Kaygusuz I, Tezcan H, Cetiner M, Kocakaya O, Uzay A, Bayik M. Bortezomib: a new therapeutic option for POEMS syndrome. European Journal of Haematology 2010;84(2):175‐7. - PubMed
Kim 2006
    1. Kim SY, Lee SA, Ryoo HM, Lee KH, Hyun MS, Bae SH. Thalidomide for POEMS syndrome. Annals of Hematology 2006;85(8):545‐6. - PubMed
Koike 2000
    1. Koike H, Sobue G. Crow‐Fukase syndrome. Neuropathology 2000;20 Suppl:S69‐72. - PubMed
Kulkarni 2011
    1. Kulkarni GB, Mahadevan A, Taly AB, Yasha TC, Seshagiri KS, Nalini A, et al. Clinicopathological profile of polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes (POEMS) syndrome. Journal of Clinical Neuroscience 2011;18(3):356‐60. - PubMed
Kuwabara 1997
    1. Kuwabara S, Hattori T, Shimoe Y, Kamitsukasa I. Long term melphalan‐prednisolone chemotherapy for POEMS syndrome. Journal of Neurology, Neurosurgery, and Psychiatry 1997;63(3):385‐7. - PMC - PubMed
Kuwabara 2006
    1. Kuwabara S, Misawa S, Kanai K, Kikkawa Y, Nishimura M, Nakaseko C, et al. Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology 2006;66(1):105‐7. - PubMed
Kuwabara 2008a
    1. Kuwabara S, Misawa S, Kanai K, Kikkawa Y, Sawai S, Hattori T, et al. Neurological recovery after autologous peripheral blood stem cell transplantation in POEMS syndrome. Neurology 2008;71(21):1961‐5. - PubMed
Kuwabara 2008b
    1. Kuwabara S, Misawa S, Kanai K, Sawai S, Hattori T, Nishimura M, et al. Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. Journal of Neurology, Neurosurgery, and Psychiatry 2008;79(11):1255‐7. - PubMed
Kuwabara 2011
    1. Kuwabara S, Misawa S. Chronic inflammatory demyelinating polyneuropathy: clinical subtypes and their correlation with electrophysiology. Clinical and Experimental Neuroimmunology 2011;2(2):41‐48.
Li 2011a
    1. Li J, Zhang W, Jiao L, Duan MH, Guan HZ, Zhu WG, et al. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood 2011;117(24):6445‐9. - PMC - PubMed
Li 2011b
    1. Li J, Zhou DB, Huang Z, Jiao L, Duan MH, Zhang W, et al. Clinical characteristics and long‐term outcome of patients with POEMS syndrome in China. Annals of Hematology 2011;90(7):819‐26. - PubMed
Mahdi‐Rogers 2009
    1. Mahdi‐Rogers M, Kazmi M, Ferner R, Hughes RA, Renaud S, Steck AJ, et al. Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. Journal of the Peripheral Nervous System 2009;14(2):118‐24. - PubMed
Mauermann 2012
    1. Mauermann ML, Sorenson EJ, Dispenzieri A, Mandrekar J, Suarez GA, Dyck PJ, et al. Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP. Journal of Neurology, Neurosurgery, and Psychiatry 2012;83(5):476‐9. - PubMed
Nakajima 2007
    1. Nakajima H, Ishida S, Furutama D, Sugino M, Kimura F, Yokote T, et al. Expression of vascular endothelial growth factor by plasma cells in the sclerotic bone lesion of a patient with POEMS syndrome. Journal of Neurology 2007;254(4):531‐3. - PubMed
Nakanishi 1984
    1. Nakanishi T, Sobue I, Toyokura Y, Nishitani H, Kuroiwa Y, Satoyoshi E, et al. The Crow‐Fukase syndrome: a study of 102 cases in Japan. Neurology 1984;34(6):712‐20. - PubMed
Nasu 2012
    1. Nasu S, Misawa S, Sekiguchi Y, Shibuya K, Kanai K, Fujimaki Y, et al. Different neurological and physiological profiles in POEMS syndrome and CIDP. Journal of Neurology, Neurosurgery, and Psychiatry 2012;83(5):476‐9. - PubMed
Ohguchi 2011
    1. Ohguchi H, Ohba R, Onishi Y, Fukuhara N, Okitsu Y, Yamamoto J, et al. Successful treatment with bortezomib and thalidomide for POEMS syndrome. Annals of Hematology 2011;90(9):1113‐4. - PubMed
Ohwada 2009
    1. Ohwada C, Nakaseko C, Sakai S, Takeda Y, Abe D, Takeuchi M, et al. Successful combination treatment with bevacizumab, thalidomide and autologous PBSC for severe POEMS syndrome. Bone Marrow Transplantation 2009;43(9):739‐40. - PubMed
Samaras 2007
    1. Samaras P, Bauer S, Stenner‐Liewen F, Steiner R, Zweifel M, Renner C, et al. Treatment of POEMS syndrome with bevacizumab. Haematologica 2007;92(10):1438‐9. - PubMed
Scarlato 2005
    1. Scarlato M, Previtali SC, Carpo M, Pareyson D, Briani C, Bo R, et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain 2005;128(8):1911‐20. - PubMed
Sinisalo 2004
    1. Sinisalo M, Hietaharju A, Sauranen J, Wirta O. Thalidomide in POEMS syndrome: case report. American Journal of Hematology 2004;76(1):66‐8. - PubMed
Sobas 2010
    1. Sobas MA, Alonso Vence N, Diaz Arias J, Bendaña Lopez A, Fraga Rodriguez M, Bello Lopez JL. Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to POEMS syndrome (MCD‐POEMS variant). Annals of Hematology 2010;89(2):217‐9. - PubMed
Soubrier 1994
    1. Soubrier MJ, Dubost JJ, Sauvezie BJ. POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS Syndrome. The American Journal of Medicine 1994;97(6):543‐53. - PubMed
Soubrier 1999
    1. Soubrier M, Sauron C, Souweine B, Larroche C, Wechsler B, Guillevin L, et al. Growth factors and proinflammatory cytokines in the renal involvement of POEMS syndrome. American Journal of Kidney Diseases 1999;34(4):633‐8. - PubMed
Straume 2006
    1. Straume O, Bergheim J, Ernst P. Bevacizumab therapy for POEMS syndrome. Blood 2006;107(12):4972‐4. - PubMed
Sung 2002
    1. Sung JY, Kuwabara S, Ogawara K, Kanai K, Hattori T. Patterns of nerve conduction abnormalities in POEMS syndrome. Muscle & Nerve 2002;26(2):189‐93. - PubMed
Takatsuki 1983
    1. Takatsuki K, Sanada I. Plasma cell dyscrasia with polyneuropathy and endocrine disorder: clinical and laboratory features of 109 reported cases. Japanese Journal of Clinical Oncology 1983;13(3):543‐55. - PubMed
Tang 2009
    1. Tang X, Shi X, Sun A, Qiu H, Gu B, Zhou H, et al. Successful bortezomib‐based treatment in POEMS syndrome. European Journal of Haematology 2009;83(6):609‐10. - PubMed
Vital 2003
    1. Vital C, Vital A, Ferrer X, Viallard JF, Pellegrin JL, Bouillot S, et al. Crow‐Fukase (POEMS) syndrome: a study of peripheral nerve biopsy in five new cases. Journal of the Peripheral Nervous System 2003;8(3):136‐44. - PubMed
Watanabe 1996
    1. Watanabe O, Arimura K, Kitajima I, Osame M, Maruyama I. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 1996;347(9002):702. - PubMed
Watanabe 1998
    1. Watanabe O, Maruyama I, Arimura K, Kitajima I, Arimura H, Hanatani M, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow‐Fukase (POEMS) syndrome. Muscle & Nerve 1998;21(11):1390‐7. - PubMed
Yuan 2009
    1. Yuan ZG, Dun XY, Li YH, Hou J. Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report. Journal of Hematology & Oncology 2009;2:19. - PMC - PubMed

References to other published versions of this review

Kuwabara 2008
    1. Kuwabara S, Dispenzieri A, Arimura K, Misawa S. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M‐protein, and skin changes) syndrome. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD006828.pub2] - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources